X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (68) 68
breast cancer (59) 59
female (58) 58
humans (58) 58
index medicus (50) 50
middle aged (46) 46
breast neoplasms - drug therapy (43) 43
cancer (37) 37
breast neoplasms - pathology (36) 36
adult (35) 35
chemotherapy (34) 34
aged (33) 33
prognosis (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
disease-free survival (21) 21
life sciences (21) 21
neoadjuvant therapy (21) 21
survival (21) 21
treatment outcome (21) 21
neoadjuvant chemotherapy (20) 20
neoplasm staging (17) 17
retrospective studies (17) 17
breast neoplasms - mortality (15) 15
breast neoplasms - surgery (15) 15
follow-up studies (15) 15
aged, 80 and over (14) 14
chemotherapy, adjuvant (14) 14
metastasis (13) 13
women (13) 13
care and treatment (12) 12
endocrine therapy (12) 12
hematology, oncology and palliative medicine (12) 12
therapy (12) 12
pathological response (11) 11
survival rate (11) 11
tamoxifen (11) 11
[ sdv.can ] life sciences [q-bio]/cancer (10) 10
combined modality therapy (10) 10
induction chemotherapy (10) 10
patients (10) 10
preoperative chemotherapy (10) 10
prospective studies (10) 10
taxoids - administration & dosage (10) 10
tumors (10) 10
adjuvant treatment (9) 9
carcinoma (9) 9
docetaxel (9) 9
erbb-2 protein (9) 9
mastectomy (9) 9
surgery (9) 9
analysis (8) 8
cancer therapies (8) 8
clinical trials (8) 8
health aspects (8) 8
lymphatic metastasis (8) 8
metastatic breast cancer (8) 8
postmenopausal women (8) 8
survival analysis (8) 8
anastrozole (7) 7
antimitotic agents (7) 7
antineoplastic agents (7) 7
bevacizumab (7) 7
breast (7) 7
cyclophosphamide - administration & dosage (7) 7
follow-up (7) 7
medicine & public health (7) 7
receptor, erbb-2 - metabolism (7) 7
time factors (7) 7
trastuzumab (7) 7
young adult (7) 7
adjuvant chemotherapy (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
carcinoma, ductal, breast - drug therapy (6) 6
clinical trials, phase ii as topic (6) 6
fluorouracil - administration & dosage (6) 6
france (6) 6
letrozole (6) 6
multivariate analysis (6) 6
neoadjuvant therapy - methods (6) 6
radiotherapy (6) 6
research (6) 6
studies (6) 6
surgical adjuvant breast (6) 6
trial (6) 6
usage (6) 6
[sdv.can]life sciences [q-bio]/cancer (5) 5
breast neoplasms - therapy (5) 5
carcinoma, lobular - drug therapy (5) 5
diagnosis (5) 5
epirubicin - administration & dosage (5) 5
exemestane (5) 5
inflammatory breast cancer (5) 5
lymph nodes - pathology (5) 5
medical prognosis (5) 5
medicine (5) 5
metastases (5) 5
multicenter (5) 5
overall survival (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Martin, Miguel and Holmes, Frankie A and Ejlertsen, Bent and Delaloge, Suzette and Moy, Beverly and Iwata, Hiroji and von Minckwitz, Gunter and Chia, Stephen K L and Mansi, Janine and Barrios, Carlos H and Gnant, Michael and Tomašević, Zorica and Denduluri, Neelima and Šeparović, Robert and Gokmen, Erhan and Bashford, Anna and Ruiz Borrego, Manuel and Kim, Sung-Bae and Kim, Seung Jin and Jakobsen, Erik Hugger and Ciceniene, Audrone and Inoue, Kenichi and Overkamp, Friedrich and Heijns, Joan B and Armstrong, Anne C and Link, John S and Joy, Anil Abraham and Bryce, Richard and Wong, Alvin and Moran, Susan and Yao, Bin and Xu, Feng and Xu, Binghe and Auerbach, Alan and Buyse, Marc and Chan, Arlene and Harvey, Vernon and Tomek, Rudolf and Robert, Nicholas J and Gore, Ira and Smith, John W and Smith, Julie C and Masuda, Norikazu and Di Sean Kendall, S and Harker, William Graydon and Petrakova, Katarina and Guerrero Zotano, Angel and Simon, Amparo Ruiz and Konstantinovic, Zora Neskovic and Iannotti, Nicholas O and Tassone, Pierfrancesco and Rodriguez, Gladys I and Jáñez Martinez, Noelia and Crespo Massieu, Carmen and Smickoska, Snezana and Somali, Isil and Yilmaz, Ugur and Alonso, Mirta Garcia and Rosales, Adolfo Murias and Cold, Soeren and Knoop, Ann Soegaard and Patt, Debra and Hellerstedt, Beth A and Morales Murillo, Serafin and Mayer, Ingrid A and Means-Powell, Julie Ann and Hui, Rina and Senecal, Francis M and De Boer, Richard Hendry and Shen, Zhenzhou and Luczak, Adam Andrzej and Chui, Joanna W.Y and Chui, Stephen and Tsang, Janice Wing-hang and Lang, Istvan and Rai, Yoshiaki and Hozumi, Yasuo and Ten Tije, Albert J and Bhandari, Manish and Osborne, Cynthia R.C and Ohtani, Shoichiro and Higaki, Kenji and Watanabe, Junichiro and Watanabe, Kenichi and Taguchi, Tetsuya and Taguchi, Kazunori and Takahashi, Masato and Filipovic, Sladjana and Hansen, Vincent L and Rao, Vijayarama Phooshkooru and Gupta, Manish and Petrov, Petar and Coudert, Bruno and Vojnovic, Zeljko and Polya, Zsofia and Miyaki, Toshiko and Yamamoto, Naohito and Brincat, Stephen and Lesniewski-Kmak, Krzysztof and Chmielowska, Ewa and ... and ExteNET Study Grp and ExteNET Study Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1688 - 1700
Journal Article
Oncology (Switzerland), ISSN 0030-2414, 04/2017, Volume 92, Issue 5, p. 310
Journal Article
by Pivot, Xavier and Romieu, Gilles and Debled, Marc and Pierga, Jean-Yves and Kerbrat, Pierre and Bachelot, Thomas and Lortholary, Alain and Espié, Marc and Fumoleau, Pierre and Serin, Daniel and Jacquin, Jean-Philippe and Jouannaud, Christelle and Rios, Maria and Abadie-Lacourtoisie, Sophie and Venat-Bouvet, Laurence and Cany, Laurent and Catala, Stéphanie and Khayat, David and Gambotti, Laetitia and Pauporté, Iris and Faure-Mercier, Celine and Paget-Bailly, Sophie and Henriques, Julie and Grouin, Jean Marie and Piprot, C and Cals, L and Chaigneau, L and Demarchi, F and N'Guyen, T and Stein, U and Villanueva, C and Bréau, JL and Chouahnia, AK and Saintigny, P and Boué, F and deSaint-Hilaire, P and Guimont, I and Grossat, N and Valenza, B and Lévy, E and Médioni, J and Delbaldo, C and Grenier, J and Pouessel, D and Lavau-Denès, S and Falandry, C and Fournel-Fédérico, C and Freyer, G and Tartas, S and Trillet-Lenoir, V and Bons, F and Auclerc, G and Chièze, S and Raban, N and Tournigand, C and Trager-Maury, S and Bousquet, G and Cuvier, C and Giacchetti, S and Hocini, A and LeMaignan, C and Misset, JL and Avenin, D and Beerblock, C and Gligorov, J and Rivera, P and Roché, H and Bougnoux, P and Hajjaji, N and Capitain, O and Delva, R and Maillart, P and Soulié, P and Bonnefoi, H and Durand, M and Madranges, N and Mauriac, L and Chollet, P and Dillies, AF and Durando, X and Ferrière, JP and Mouret-Reynier, C and Nabholtz, JM and Van Praagh, I and Cottu, P and Diéras, V and Durieux, A and Galotte, M and Girre, V and Henry, S and Iurisci, I and Jouve, M and Laurence, V and Mignot, L and Piperno-Neumann, S and Tresca, P and Coudert, B and Ferrant, E and Mayer, F and Vanneuville, AC and ... and PHARE Trial Investigators and PHARE trial investigators
The Lancet, ISSN 0140-6736, 06/2019, Volume 393, Issue 10191, pp. 2591 - 2598
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2017, Volume 28, Issue 1, pp. 103 - 109
Journal Article
PLoS Medicine, ISSN 1549-1277, 12/2016, Volume 13, Issue 12, pp. e1002201 - e1002201
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2014, Volume 32, Issue 30, pp. 3374 - 3381
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2016, Volume 27, Issue 9, pp. 1725 - 1732
Journal Article
European Journal of Cancer, ISSN 0959-8049, 07/2017, Volume 79, p. 72
Aim: Women of reproductive age with breast cancer generally receive gonadotoxic chemotherapy. Fertility issues are of great concern for them. However, little... 
Women | Chemotherapy | Cyclophosphamide | Preservation | Fertility | Breast | Evolution | Breast cancer | Tamoxifen | Patients | Age | Cancer
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 87 - 100
Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit... 
ACTIVATION | EVEROLIMUS | PATHWAY | RESISTANCE | ENDOCRINE THERAPY | AKT | MUTATIONS | COMBINATION | TUMORS | BKM120 | ONCOLOGY | Estradiol - analogs & derivatives | TOR Serine-Threonine Kinases - metabolism | Estrogen Receptor Antagonists - administration & dosage | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Protein Kinase Inhibitors - adverse effects | TOR Serine-Threonine Kinases - antagonists & inhibitors | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Time Factors | Estradiol - adverse effects | Female | Phosphatidylinositol 3-Kinase - metabolism | Morpholines - adverse effects | Aminopyridines - administration & dosage | Double-Blind Method | Biomarkers, Tumor - analysis | Morpholines - administration & dosage | Estradiol - administration & dosage | Estrogen Receptor Antagonists - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Antimitotic agents | Analysis | Clinical trials | Breast cancer | Product development | Postmenopausal women | Hormones | Antineoplastic agents | Life Sciences | Cancer
Journal Article